Cardiac assist device infections

Current Infectious Disease Reports

Volumn 11, Issue 4, 2009, Pages 268-273

  Shoham, Shmuel ^a   Miller, Leslie W ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; FLUCONAZOLE; INTERLEUKIN 10; INTERLEUKIN 2; LEVOFLOXACIN; PSEUDOMONIC ACID; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ASSISTED CIRCULATION; BIOFILM; CANDIDA; CONGESTIVE HEART FAILURE; CORYNEBACTERIUM; DEVICE INFECTION; ENTEROCOCCUS; EVENING DOSAGE; HEART ASSIST DEVICE; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MICROBIAL IMMUNITY; PATHOGENESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS;

EID: 67649101568     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0040-4     Document Type: Review

References (35)

1. Miller LW, Pagani FD, Russell SD, et al.: Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007, 357:885-896.
2. Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
3. Simon D, Fischer S, Grossman A, et al.: Left ventricular assist device-related infection: Treatment and outcome. Clin Infect Dis 2005, 40:1108-1115.
4. Oz MC, Gelijns AC, Miller L, et al.: Left ventricular assist devices as permanent heart failure therapy: The price of progress. Ann Surg 2003, 238:577-583; discussion 583-585.
5. Monkowski DH, Axelrod P, Fekete T, et al.: Infections associated with ventricular assist devices: Epidemiology and effect on prognosis after transplantation. Transpl Infect Dis 2007, 9:114-120.
6. Shoham S, Shaffer R, Sweet L, et al.: Candidemia in patients with ventricular assist devices. Clin Infect Dis 2007, 44:e9-12.
7. Zierer A, Melby SJ, Voeller RK, et al.: Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg 2007, 84:515-20.
8. Arrecubieta C, Asai T, Bayern M, et al.: The role of Staphylococcus aureus adhesins in the pathogenesis of ventricular assist device-related infections. J Infect Dis 2006, 193:1109-1119.
9. Asai T, Lee MH, Arrecubieta C, et al.: Cellular coating of the left ventricular assist device textured polyurethane membrane reduces adhesion of Staphylococcus aureus. J Thorac Cardiovasc Surg 2007, 133:1147-1153.
10. Padera RF: Infection in ventricularTassist devices: the role of biofilm. Cardiovasc Pathol 2006, 15:264-270.
11. Kimball PM, Flattery M, McDougan F, Kasirajan V. Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann Thorac Surg 2008, 85:1656-1661.
12. Kimball P, Flattery M, Kasirajan V: T-cell response to staphylococcal enterotoxin B is reduced among heart failure patients on ventricular device support. Transplant Proc 2006, 38:3695-3696.
13. Yamani MH, Chuang HH, Ozduran V, et al.: The impact of hypogammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation. J Heart Lung Transplant 2006, 25:820-824.
14. Gonzalez-Stawinski GV, Cook DJ, Chang AS, et al.: Ventricular assist devices and aggressive immunosuppression: Looking beyond overall survival. J Heart Lung Transplant 2006, 25:613-618.
15. Schulman AR, Martens TP, Christos PJ, et al.: Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. J Thorac Cardiovasc Surg 2007, 133:841-842.
16. Shive MS, Salloum ML, Anderson JM: Shear stress-induced apoptosis of adherent neutrophils: A mechanism for persistence of cardiovascular device infections. Proc Natl Acad Sci U S A 2000, 97:6710-6715.
17. Shive MS, Brodbeck WG, Colton E, Anderson JM: Shear stress and material surface effects on adherent human monocyte apoptosis. J Biomed Mater Res 2002, 60:148-158.
18. Shive MS, Hasan SM, Anderson JM: Shear stress effects on bacterial adhesion, leukocyte adhesion, and leukocyte oxidative capacity on a polyetherurethane. J Biomed Mater Res 1999, 46:511-519.
19. Pae WE, Connell JM, Adelowo A, et al.: Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant 2007, 26:219-229.
20. Holman WL, Pamboukian SV, Blood M, et al.: Managing device infections: are we progressing or is infection an insurmountable obstacle? Asaio J 2005, 51:452-455.
21. Holman WL, Rayburn BK, McGiffin DC, et al.: Infection in ventricular assist devices: Prevention and treatment. Ann Thorac Surg 2003, 75:S48-S57.
22. Holman WL, Pamboukian SV, Bellot SC, et al.: Use of an intraperitoneal ventricular assist device with a polytetra-fluoroethylene barrier decreases infections. J Heart Lung Transplant 2008, 27:268-271.
23. BaradarCan S, Stahovich M, Krause S, et al.: Case series: clinical management of persistent mechanical assist device driveline drainage using vacuum-assisted closure therapy. Asaio J 2006, 52:354-356.
24. Holman WL, Park SJ, Long JW, et al.: Infection in permanent circulatory support: Experience from the REMATCH trial. J Heart Lung Transplant 2004, 23:1359-1365.
25. Huang R, Deng M, Rogers JG, et al.: Effect of age on outcomes after left ventricular assist device placement. Transplant Proc 2006, 38:1496-1498.
26. Granfeldt H, Hellgren L, Dellgren G, et al.: Experience with the Impella(R) recovery axial-flow system for acute heart failure at three cardiothoracic centers in Sweden. Scand Cardiovasc J 2009:1-7.
27. El-Hamamsy I, Jacques F, Perrault LP, et al.: Results following implantation of mechanical circulatory support systems: The Montreal Heart Institute experience. Can J Cardiol 2009, 25:107-110.
28. Osaki S, Edwards NM, Velez M, et al.: Improved survival in patients with ventricular assist device therapy: The University of Wisconsin experience. Eur J Cardiothorac Surg 2008, 34:281-288.
29. Lietz K, Long JW, Kfoury AG, et al.: Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007, 116:497-505.
30. Chinn R, Dembitsky W, Eaton L, et al.: Multicenter experience: prevention and management of left ventricular assist device infections. Asaio J 2005, 51:461-470.
31. Manahan MA, Goldberg NH, Silverman RP. Successful salvage of ventricular-assist devices in the setting of pump pocket infection. Ann Plast Surg 2006, 57:435-439.
32. Didisheim P, Rose EA, Long JW, et al.: Infection with clinical ventricular assist devices: Clinical therapy. Asaio J 2001, 47:195-196.
33. Yuh DD, Albaugh M, Ullrich S, Conte JV: Treatment of ventricular assist device driveline infection with vacuum-assisted closure system. Ann Thorac Surg 2005, 80:1493-1495.
34. McGee EC, Jr., Cotts W, Tambur AR, et al.: Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. J Heart Lung Transplant 2008, 27:568-571.
35. Sajjadian A, Valerio IL, Acurturk O, et al.: Omental transposition flap for salvage of ventricular assist devices. Plast Reconstr Surg 2006, 118:919-926; discussion 927.